News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seattle Genetics, Inc. (SGEN) and Agensys, Inc., an Affiliate of Astellas Pharma Inc. (YPH.BE), Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration


6/27/2013 9:54:41 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOTHELL, Wash. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), today announced that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies’ existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 1 trial of ASG-15ME.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES